These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1110 related items for PubMed ID: 28362144

  • 1. Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG).
    Eriksson C, Marsal J, Bergemalm D, Vigren L, Björk J, Eberhardson M, Karling P, Söderman C, SWIBREG Vedolizumab Study Group, Myrelid P, Cao Y, Sjöberg D, Thörn M, Karlén P, Hertervig E, Strid H, Ludvigsson JF, Almer S, Halfvarson J.
    Scand J Gastroenterol; 2017; 52(6-7):722-729. PubMed ID: 28362144
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety.
    Christensen B, Colman RJ, Micic D, Gibson PR, Goeppinger SR, Yarur A, Weber CR, Cohen RD, Rubin DT.
    Inflamm Bowel Dis; 2018 Mar 19; 24(4):849-860. PubMed ID: 29562271
    [Abstract] [Full Text] [Related]

  • 7. One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study.
    Amiot A, Serrero M, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Moreau J, Vuitton L, Viennot S, Aubourg A, Pelletier AL, Bouguen G, Abitbol V, Gagniere C, Bouhnik Y, OBSERV-IBD study group and the GETAID.
    Aliment Pharmacol Ther; 2017 Aug 19; 46(3):310-321. PubMed ID: 28593685
    [Abstract] [Full Text] [Related]

  • 8. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.
    Stallmach A, Langbein C, Atreya R, Bruns T, Dignass A, Ende K, Hampe J, Hartmann F, Neurath MF, Maul J, Preiss JC, Schmelz R, Siegmund B, Schulze H, Teich N, von Arnim U, Baumgart DC, Schmidt C.
    Aliment Pharmacol Ther; 2016 Dec 19; 44(11-12):1199-1212. PubMed ID: 27714831
    [Abstract] [Full Text] [Related]

  • 9. Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice.
    Vivio EE, Kanuri N, Gilbertsen JJ, Monroe K, Dey N, Chen CH, Gutierrez AM, Ciorba MA.
    J Crohns Colitis; 2016 Apr 19; 10(4):402-9. PubMed ID: 26681763
    [Abstract] [Full Text] [Related]

  • 10. Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation.
    Bortlik M, Duricova D, Machkova N, Hruba V, Lukas M, Mitrova K, Romanko I, Bina V, Malickova K, Kolar M, Lukas M.
    Scand J Gastroenterol; 2016 Apr 19; 51(2):196-202. PubMed ID: 26329773
    [Abstract] [Full Text] [Related]

  • 11. Vedolizumab induction therapy for inflammatory bowel disease in clinical practice--a nationwide consecutive German cohort study.
    Baumgart DC, Bokemeyer B, Drabik A, Stallmach A, Schreiber S, Vedolizumab Germany Consortium.
    Aliment Pharmacol Ther; 2016 May 19; 43(10):1090-102. PubMed ID: 27038247
    [Abstract] [Full Text] [Related]

  • 12. High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO).
    Ylisaukko-Oja T, Aaltonen J, Nuutinen H, Blomster T, Jussila A, Pajala M, Salminen K, Moilanen V, Hakala K, Kellokumpu M, Toljamo K, Rautiainen H, Kuisma J, Peräaho M, Molander P, Silvennoinen J, Liukkonen V, Henricson H, Tillonen J, Esterinen M, Nielsen C, Hirsi E, Lääne M, Suhonen UM, Vihriälä I, Mäkelä P, Puhto M, Punkkinen J, Sulonen H, Herrala S, Jokelainen J, Tamminen K, Sipponen T.
    Scand J Gastroenterol; 2018 Feb 19; 53(2):158-167. PubMed ID: 29258369
    [Abstract] [Full Text] [Related]

  • 13. Vedolizumab, an option in patients with inflammatory bowel disease intolerant to thiopurines and refractory to biological agents.
    Iborra M, Beltrán B, Maroto N, Navarro-Cortés P, Boscá-Watts M, Ferrer-Bradley I, García-Morales N, Sáez-González E, Hinojosa J, Mínguez M, Nos P.
    Gastroenterol Hepatol; 2018 Nov 19; 41(9):535-543. PubMed ID: 30031573
    [Abstract] [Full Text] [Related]

  • 14. Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.
    Rosario M, French JL, Dirks NL, Sankoh S, Parikh A, Yang H, Danese S, Colombel JF, Smyth M, Sandborn WJ, Feagan BG, Reinisch W, Sands BE, Sans M, Fox I.
    J Crohns Colitis; 2017 Aug 01; 11(8):921-929. PubMed ID: 28333288
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort.
    Shelton E, Allegretti JR, Stevens B, Lucci M, Khalili H, Nguyen DD, Sauk J, Giallourakis C, Garber J, Hamilton MJ, Tomczak M, Makrauer F, Burakoff RB, Levine J, de Silva P, Friedman S, Ananthakrishnan A, Korzenik JR, Yajnik V.
    Inflamm Bowel Dis; 2015 Dec 01; 21(12):2879-85. PubMed ID: 26288002
    [Abstract] [Full Text] [Related]

  • 16. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
    Molander P, Sipponen T, Kemppainen H, Jussila A, Blomster T, Koskela R, Nissinen M, Rautiainen H, Kuisma J, Kolho KL, Färkkilä M.
    J Crohns Colitis; 2013 Oct 01; 7(9):730-5. PubMed ID: 23182163
    [Abstract] [Full Text] [Related]

  • 17. Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study.
    Amiot A, Serrero M, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Moreau J, Vuitton L, Viennot S, Bouguen G, Abitbol V, Fumery M, Gagniere C, Bouhnik Y, OBSERV-IBD study group, the GETAID.
    Aliment Pharmacol Ther; 2019 Jul 01; 50(1):40-53. PubMed ID: 31165509
    [Abstract] [Full Text] [Related]

  • 18. Clinical effectiveness of golimumab in Crohn's disease: an observational study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG).
    Rundquist S, Eriksson C, Nilsson L, Angelison L, Jäghult S, Björk J, Grip O, Hjortswang H, Strid H, Karlén P, Montgomery S, Halfvarson J.
    Scand J Gastroenterol; 2018 Jul 01; 53(10-11):1257-1263. PubMed ID: 30353751
    [Abstract] [Full Text] [Related]

  • 19. Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements.
    Mader O, Juillerat P, Biedermann L, Michetti P, Hruz P, Pittet V, Rogler G, Zahnd-Straumann N, Seibold F.
    United European Gastroenterol J; 2021 Apr 01; 9(3):398-406. PubMed ID: 33203339
    [Abstract] [Full Text] [Related]

  • 20. Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease.
    Schneider AM, Weghuber D, Hetzer B, Entenmann A, Müller T, Zimmermann G, Schütz S, Huber WD, Pichler J.
    BMC Gastroenterol; 2018 Sep 15; 18(1):140. PubMed ID: 30219028
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 56.